ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
24 announcements
Unichem Laboratories received five procedural observations from the USFDA following an inspection of its Goa formulation facility. The company plans to respond within 15 days.
Unichem Laboratories received a tax order from the Commissioner (Appeals, Thane) for a penalty and interest liability totaling ₹93.66 Crore. The company intends to file an appeal.
Unichem extended the exercise period for 3.75 lakh vested ESOP options from 30-Sep-2026 to 31-Mar-2027. The NRC approved the extension via circular resolution under the 2018 Scheme.
Unichem Laboratories clarified that the recent spurt in trading volume is purely market-driven. The company confirmed it has no undisclosed price-sensitive information to report.
Unichem Laboratories held its 63rd Annual General Meeting on August 11, 2026. The meeting covered the adoption of financial statements and re-appointments of key management personnel.
Unichem Laboratories Ltd reported revenue from operations of ₹632.6 Cr (+20.1% YoY) and net profit of ₹41.5 Cr for Q1 FY27.
Unichem Laboratories received a GST demand order for ₹0.11 Crore from the Additional Commissioner, CGST (Appeals), Dehradun. The company intends to appeal the order.
Unichem Laboratories received a partial allowance for its GSTR TRAN 1 credit appeal. The order creates a demand of ₹1.06 Crore plus interest.
Unichem Laboratories scheduled a board meeting on August 11, 2026. The board will consider and approve unaudited financial results for the quarter ended June 30, 2026.
Unichem Laboratories clarified that recent stock price increases are purely market-driven. The company confirmed compliance with all SEBI disclosure requirements and reported no undisclosed material events.
Unichem Laboratories Ltd announces its 63rd AGM on 11th August 2026. Agenda includes adopting financial statements and appointing a Director.
Unichem Labs filed its BRSR for FY 2025-26, detailing operations and sustainability. The report includes employee data and CSR activities but no financial results or corporate action.
Unichem Labs filed its Annual Report for FY 2025-26, including financial highlights. The report details standalone performance with ₹1,475.19 Cr total income for the year.
Equity Intelligence India Pvt Ltd sold 3,00,000 shares of Unichem Laboratories via open market. Its stake decreased from 0.99% to 0.56% following the transaction.
Unichem Laboratories clarified that recent trading volume increases are purely market-driven. The company confirmed compliance with all SEBI disclosure regulations regarding price-sensitive information.
Unichem Laboratories scheduled its 63rd AGM for August 11, 2026, via video conferencing. The company set August 4, 2026, as the cut-off date for shareholder voting eligibility.
Unichem Laboratories filed its Annual Secretarial Compliance Report for FY2026. The report confirms overall regulatory adherence with no material non-compliance observations reported by auditors.
Unichem Laboratories re-appointed its CEO, Managing Director, and statutory auditors during a board meeting. These leadership and audit extensions ensure operational continuity for the company.
Unichem Laboratories Ltd reported revenue from operations of ₹575.1 Cr (-2.1% YoY) and net profit of ₹10.9 Cr (-79.4% YoY) for Q4 FY26.
Unichem Laboratories reported consolidated annual revenue of ₹2,201.85 Crore and profit of ₹252.84 Crore. The Board also re-appointed Mr. Pabitrakumar Bhattacharyya as Managing Director and CEO.
Unichem Laboratories Ltd has scheduled a Board Meeting for May 22, 2026. The board will consider and approve the standalone and consolidated unaudited financial results for the quarter ended March 31, 2026, and audited results for the full financial year.
Unichem Laboratories Ltd's US subsidiary has voluntarily recalled Buspirone Hydrochloride Tablets (5 mg) due to an out-of-specification assay result identified during stability testing. No adverse events have been reported. The company maintains its focus on patient safety and quality standards throughout its supply chain.
Unichem Laboratories Ltd announced that ICRA has reaffirmed its '[ICRA]A+ (Stable)' credit rating for the company's Rs. 180 Crore bank facilities. This rating action covers Rs. 120 Crore in fund-based/non-fund based facilities and Rs. 60 Crore in unallocated limits, reflecting a stable credit outlook.
Unichem Laboratories Ltd submitted its quarterly compliance certificate under SEBI (DP) Regulations for the period ended March 31, 2026. The certificate, issued by Link Intime India, confirms that security certificates received for dematerialisation were processed and listed on stock exchanges within prescribed timelines.